Grandeur Peak Global Advisors LLC Acquires New Shares in AtriCure, Inc. $ATRC

Grandeur Peak Global Advisors LLC acquired a new position in AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 587,399 shares of the medical device company’s stock, valued at approximately $16,435,000. AtriCure makes up approximately 3.3% of Grandeur Peak Global Advisors LLC’s holdings, making the stock its 8th biggest position. Grandeur Peak Global Advisors LLC owned about 1.15% of AtriCure at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of ATRC. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure during the 2nd quarter valued at about $37,000. Smartleaf Asset Management LLC raised its holdings in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the last quarter. Harbor Investment Advisory LLC bought a new position in AtriCure during the second quarter valued at approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure in the second quarter worth approximately $43,000. Finally, Fifth Third Bancorp bought a new position in shares of AtriCure during the 1st quarter valued at $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Price Performance

NASDAQ:ATRC opened at $49.27 on Friday. The business’s 50-day moving average is $37.50 and its 200 day moving average is $32.14. AtriCure, Inc. has a 12 month low of $25.36 and a 12 month high of $49.88. The company has a market capitalization of $2.51 billion, a P/E ratio of 234.63 and a beta of 1.20. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the completion of the transaction, the director directly owned 14,015 shares of the company’s stock, valued at $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Karen Prange sold 3,564 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director owned 22,809 shares in the company, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,616 shares of company stock valued at $2,149,994 over the last quarter. 4.00% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on ATRC. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. BTIG Research raised their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday. Zacks Research downgraded shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.89.

AtriCure Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.